Ascendis Pharma A/S
ASND
Peringkat dalam Saham
#1497
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Harga Saham
$234.15
Kapitalisasi Pasar
$14.61B
Perubahan (1 hari)
1.82%
Perubahan (1 tahun)
14.10%
Negara
DK
Perdagangan Ascendis Pharma A/S (ASND)
Kategori
Healthcare
Jumlah saham beredar untuk Ascendis Pharma A/S (ASND)
Jumlah saham beredar per June 2026: 64.34M
Menurut laporan keuangan terbaru dan harga saham Ascendis Pharma A/S, jumlah saham beredar saat ini adalah 64.34M. Pada akhir December 2024, perusahaan memiliki 57.89M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Ascendis Pharma A/S (ASND) dari 2012 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 64.34M | 6.17% |
| 2025 | 60.61M | 4.69% |
| 2024 | 57.89M | 2.85% |
| 2023 | 56.29M | 0.38% |
| 2022 | 56.07M | 2.37% |
| 2021 | 54.77M | 8.21% |
| 2020 | 50.62M | 8.84% |
| 2019 | 46.51M | 13.20% |
| 2018 | 41.09M | 22.18% |
| 2017 | 33.63M | 26.58% |
| 2016 | 26.56M | 12.16% |
| 2015 | 23.68M | 39.85% |
| 2014 | 16.94M | 56.78% |
| 2013 | 10.80M | 0.00% |
| 2012 | 10.80M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | 294.59% |
US
|
|
| 396.00M | 515.43% |
US
|
|
| 478.91M | 644.29% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -3.36% |
NL
|
